Zobrazeno 1 - 10
of 279
pro vyhledávání: '"R. Donald Harvey"'
Autor:
Christina M. Knippler, Jamie L. Arnst, Isaac E. Robinson, Veronika Matsuk, Tala O. Khatib, R. Donald Harvey, Mala Shanmugam, Janna K. Mouw, Haian Fu, Thota Ganesh, Adam I. Marcus
Publikováno v:
iScience, Vol 27, Iss 4, Pp 109591- (2024)
Summary: Targeting cancer metabolism to limit cellular energy and metabolite production is an attractive therapeutic approach. Here, we developed analogs of the bisbiguanide, alexidine, to target lung cancer cell metabolism and assess a structure-act
Externí odkaz:
https://doaj.org/article/23b5922f597f4f7084cf0f89ddff9f8a
Autor:
Dejan Juric, Minal Barve, Ulka Vaishampayan, Desamparados Roda, Aitana Calvo, Noelia Martinez Jañez, Jose Trigo, Alastair Greystoke, R. Donald Harvey, Anthony J. Olszanski, Mateusz Opyrchal, Alexander Spira, Fiona Thistlethwaite, Begoña Jiménez, Jessica Huck Sappal, Karuppiah Kannan, Jason Riley, Cheryl Li, Cong Li, Richard C. Gregory, Harry Miao, Shining Wang
Publikováno v:
Cancer Medicine, Vol 13, Iss 5, Pp n/a-n/a (2024)
Abstract Mivavotinib (TAK‐659/CB‐659), a dual SYK/FLT3 inhibitor, reduced immunosuppressive immune cell populations and suppressed tumor growth in combination with anti‐PD‐1 therapy in cancer models. This dose‐escalation/expansion study inv
Externí odkaz:
https://doaj.org/article/543c6b5130f7472f8fd3b9ea9ea6f7e2
Autor:
Anna M. Avinger, Hannah Claire Sibold, Gavin Campbell, Eli Abernethy, John Bourgeois, Tekiah McClary, Shannon Blee, Margie Dixon, R. Donald Harvey, Rebecca D. Pentz
Publikováno v:
BMC Medical Ethics, Vol 24, Iss 1, Pp 1-7 (2023)
Abstract Background Although patient advocates have developed templates for standard consent forms, evaluating patient preferences for first in human (FIH) and window of opportunity (Window) trial consent forms is critical due to their unique risks.
Externí odkaz:
https://doaj.org/article/e9e7fa6552c14fb687d7b39237c750ff
Autor:
Julia S. Lee, Charlotte B. Wagner, Stacy Prelewicz, Heena P. Kurish, Robert Walchack, Danielle A. Cenin, Seema Patel, Mimi Lo, Danielle Schlafer, Belinda K.T. Li, R. Donald Harvey III, Bestis Wasef, Jian Ying, Tibor Kovacsovics
Publikováno v:
Haematologica, Vol 108, Iss 12 (2023)
Externí odkaz:
https://doaj.org/article/e7401b710f8c401087de767fe08de484
Autor:
Karthick Vishwanathan, Mireille Cantarini, Karen So, Eric Masson, Jennifer Fetterolf, Suresh S. Ramalingam, R. Donald Harvey
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 1, Pp 41-46 (2020)
A phase I, open‐label study (NCT02197234) assessed the effects of osimertinib on simvastatin exposure in patients with advanced epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer and disease progression post‐EGFR tyros
Externí odkaz:
https://doaj.org/article/ea83b7b40c5c49ea8689ac0cb8a348d1
Autor:
Michael S. Gordon, Geoffrey I. Shapiro, John Sarantopoulos, Dejan Juric, Brian Lu, Angeliki Zarotiadou, Jamie N. Connarn, Yvan Le Bruchec, Calin Dan Dumitru, R. Donald Harvey
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
BackgroundCitarinostat (CC-96241; previously ACY-241), an oral inhibitor of histone deacetylases (HDACs) with selectivity for HDAC6, has demonstrated synergistic anticancer activity with paclitaxel in multiple solid tumor models. Combination therapy
Externí odkaz:
https://doaj.org/article/0ab9e0c5140445e598f9434b136856c5
Autor:
Mehmet Asim Bilen, Julie M. Shabto, Dylan J. Martini, Yuan Liu, Colleen Lewis, Hannah Collins, Mehmet Akce, Haydn Kissick, Bradley C. Carthon, Walid L. Shaib, Olatunji B. Alese, Conor E. Steuer, Christina Wu, David H. Lawson, Ragini Kudchadkar, Viraj A. Master, Bassel El-Rayes, Suresh S. Ramalingam, Taofeek K. Owonikoko, R. Donald Harvey
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background Selecting the appropriate patients to receive immunotherapy (IO) remains a challenge due to the lack of optimal biomarkers. The presence of liver metastases has been implicated as a poor prognostic factor in patients with metastat
Externí odkaz:
https://doaj.org/article/3a89538b1b6f4594bd638b17c5ad5f05
Autor:
Sylvie M. Mimche, Choon-myung Lee, Ken H. Liu, Patrice N. Mimche, R. Donald Harvey, Thomas J. Murphy, Beatrice A. Nyagode, Dean P. Jones, Tracey J. Lamb, Edward T. Morgan
Publikováno v:
Malaria Journal, Vol 18, Iss 1, Pp 1-16 (2019)
Abstract Background Given the central importance of anti-malarial drugs in the treatment of malaria, there is a need to understand the effect of Plasmodium infection on the broad spectrum of drug metabolizing enzymes. Previous studies have shown redu
Externí odkaz:
https://doaj.org/article/391564a345ce4823927cc7605d2c0191
Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing
Autor:
John W. Cook, Megan K. McGrath, Margie D. Dixon, Jeffrey M. Switchenko, R. Donald Harvey, Rebecca D. Pentz
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Background: With increasing numbers of oncology biosimilars in the approval pipeline, it is important to investigate oncology clinicians’ understanding of biosimilars and what information they need prior to adoption. Methods: Between January and Ma
Externí odkaz:
https://doaj.org/article/735a9bd9260a44978f05ad10dcc90d52
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 6 (2014)
Several classes of antineoplastic agents are universally referred to as vesicants with ample supporting literature. However, the literature surrounding the taxanes is controversial. While the American Society of Clinical Oncology and Oncology Nursing
Externí odkaz:
https://doaj.org/article/a0b74c7cbf80471fa0ca5564f86facdd